Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Mark T Reding"'
Autor:
Mark T. Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Cedric Hermans
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date on ef
Externí odkaz:
https://doaj.org/article/3106ae96a0814ef99d906c776d898f7c
Autor:
Alexandra A. Bishop, Eric Krohn, Victor R. Vakayil, Kyle Pribyl, Mark T. Reding, Christopher Tignanelli, James V. Harmon
Publikováno v:
Clinical Case Reports, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract We report long‐term follow‐up of a patient who underwent a tailored laparoscopic procedure for symptomatic cholelithiasis, massive splenomegaly, and a planned pregnancy. There were no complications, and the patient remained symptom‐fre
Externí odkaz:
https://doaj.org/article/7efce10918a646ca8779021bc1b13a29
Autor:
Duc Q. Tran, Craig C. Benson, Judith A. Boice, Meera Chitlur, Amy L. Dunn, Miguel A. Escobar, Kalpna Gupta, Jill M. Johnsen, James Jorgenson, Scott D. Martin, Suzanne Martin, Shannon L. Meeks, Alfredo A. Narvaez, Doris V. Quon, Mark T. Reding, Ulrike M. Reiss, Brittany Savage, Kim Schafer, Bruno Steiner, Courtney Thornburg, Lena M. Volland, Annette von Drygalski
Publikováno v:
Expert Review of Hematology. 16:19-37
Autor:
Mark T Reding, María Teresa Alvarez Román, Martin Sanabria, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg
Publikováno v:
Blood. 140:5612-5614
Autor:
Mark T Reding, Maria Elisa Mancuso, Suchitra Acharya, Sanjay Ahuja, Maria Teresa Álvarez-Román, Lisa N Boggio, Meera B. Chitlur, Abraham Salvador Majluf-Cruz, Amy L Dunn, Miguel Escobar, Annie Harroche, Maissaa Janbain, Craig M. Kessler, Philip Maes, Catherine E. McGuinn, Danielle Nance, Ulrike Nowak-Göttl, Robert F. Sidonio, Jr., Duc Q Tran, Michael Wang, Jerzy Windyga, Hongying Wang, Thomas Wilkinson, Steven W. Pipe
Publikováno v:
Blood. 140:5597-5599
Autor:
Jerzy Windyga, Ian S Mitchell, Yevhenii Averianov, Adam Giermasz, Maria Fernanda Lopez Fernandez, Laura Villarreal Martinez, W. Allan Alexander, Wolfgang Miesbach, Oleksandra Stasyshyn, Ismail Haroon Mitha, Daniel P. Hart, James V. Luck, Janna M. Journeycake, Miguel A. Escobar, Daniel Bonzo, Cindy A. Leissinger, Cédric Hermans, Mark T. Reding, J.-F. Schved, Kateryna V. Vilchevska, Craig M. Kessler, Jonathan M. Ducore, Doris Quon, Thomas A. Wilkinson, Johnny Mahlangu, Ahmad Al-Sabbagh, Michael Wang
Publikováno v:
Haemophilia, Vol. 27, no. 6, p. 911-920 (2021)
Introduction Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two BPAs have been available; these are reported to have
Autor:
Mark T. Reding, Judith Baker, Michael Recht, Miguel A. Escobar, Leonard A. Valentino, Joseph N Pugliese, Constance B Thibodeaux, Mark W. Skinner, Diane J. Nugent, Susan Karp, Michelle Rice, Regina Butler, Neil Frick, Kollet Koulianos, Susan Lattimore
Publikováno v:
Journal of Blood Medicine
Rare, chronic diseases such as hemophilia and other congenital coagulation disorders require coordinated delivery of services for optimal outcomes. Hemophilia Treatment Centers (HTCs) are specialized, multidisciplinary health-care centers providing t
Autor:
Alfonso Iorio, Christoph Königs, Mark T. Reding, Dawn Rotellini, Mark W Skinner, Maria Elisa Mancuso, Erik Berntorp
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES.
People with non-severe haemophilia appear to be under-treated in many countries, and this may lead to joint damage and worsen quality of life.To review literature for clotting factor replacement prophylaxis in people with non-severe haemophilia A and
Autor:
Pål Andre Holme, Karina Meijer, Claude Negrier, Shadan Lalezari, Ingrid Pabinger, Monika Maas Enriquez, Maria Wang, Lone Hvitfeldt Poulsen, Mark T. Reding, Pavani Chalasani, Maria Elisa Mancuso
Publikováno v:
Haemophilia, 27(3), E347-E356. Wiley
Reding, M T, Pabinger, I, Holme, P A, Poulsen, L, Negrier, C, Chalasani, P, Maas Enriquez, M, Wang, M, Meijer, K, Mancuso, M E & Lalezari, S 2021, ' Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A : final results of the PROTECT VIII extension study ', Haemophilia, vol. 27, no. 3, pp. e347-e356 . https://doi.org/10.1111/hae.14297
Reding, M T, Pabinger, I, Holme, P A, Poulsen, L, Negrier, C, Chalasani, P, Maas Enriquez, M, Wang, M, Meijer, K, Mancuso, M E & Lalezari, S 2021, ' Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A : final results of the PROTECT VIII extension study ', Haemophilia, vol. 27, no. 3, pp. e347-e356 . https://doi.org/10.1111/hae.14297
Introduction: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to extend its half-life. Aim: To re
Autor:
Tammuella Chrisentery-Singleton, Lauren E. Amos, Daniel Bonzo, Miguel Escobar, Adam Giermasz, Emmanuelle Lagrue, Christine Knoll, Sonia Nasr, Michael Recht, Spencer Sullivan, Doris V. Quon, Mark T. Reding
Publikováno v:
Blood. 140:11360-11361